Cerebrospinal Fluid Concentrations and Serum Protein Binding of Lorazepam and its Conjugate
Leena Aaltonen
From the Department of Pharmacology, Turku University, Department of Anaesthesiology, Turku University Central Hospital, and Leiras Pharmaceutical Plant, Turku, Finland.
Search for more papers by this authorJussi Kanto
From the Department of Pharmacology, Turku University, Department of Anaesthesiology, Turku University Central Hospital, and Leiras Pharmaceutical Plant, Turku, Finland.
Search for more papers by this authorMatti Salo
From the Department of Pharmacology, Turku University, Department of Anaesthesiology, Turku University Central Hospital, and Leiras Pharmaceutical Plant, Turku, Finland.
Search for more papers by this authorLeena Aaltonen
From the Department of Pharmacology, Turku University, Department of Anaesthesiology, Turku University Central Hospital, and Leiras Pharmaceutical Plant, Turku, Finland.
Search for more papers by this authorJussi Kanto
From the Department of Pharmacology, Turku University, Department of Anaesthesiology, Turku University Central Hospital, and Leiras Pharmaceutical Plant, Turku, Finland.
Search for more papers by this authorMatti Salo
From the Department of Pharmacology, Turku University, Department of Anaesthesiology, Turku University Central Hospital, and Leiras Pharmaceutical Plant, Turku, Finland.
Search for more papers by this author
References
- Bertler, Aring., K.-E. Andersson & G. Wettrell: Concentration of digoxin in chroroid plexus. Lancet 1973, 2, 1453–1454.
- Bobon, J., S. Bourdouxhe, M. Breulet, M. Parent & D. P. Bobon: Pilot clinical trial of parenteral lorazepam (Temesta) in anxiety states. Psychopharmacology 1973, 33, 377–384.
- Bonting, S. L., N. M. Hawkins & M. R. Canady: Studies of sodium potassium activated adenosine triphosphatase. VII-inbibition by erythrophleum alkaloids. Biochem. Pharmacol. 1964, XX, 13–22.
- Brodie, B. B., H. Kurz & S. Schenker: The importance of dissociation constant and lipid-solubility in influencing the passage of drugs into cerebrospinal fluid. J. Pharmacol. 1960, 130, 20–25.
- Elliott, H. W.: Metabolism of lorazepam. Brit. J. Anaesth. 1976, 48, 1017–1023.
- Greenblatt, D. J., K. Franke & R. I. Shader: Analysis of lorazepam and its glucuronide metabolite by electron-capture gasliquid chromatography. Use in pharmacokinetic studies of lorazepam. J. Chromatography 1978, 146, 311–320.
- Hendel, J.: Cumulation in cerebrospinal fluid of the N-desmethylmetabolite after long-term treatment with diazepam in man. Acta pharmacol. et toxicol. 1975, 41, 17–22.
- Kangas, L., J. Kanto, T. Siirtola & A. Pekkarinen: Cerebrospinal fluid concentrations of nitrazepam in man. Acta pharmacol. et toxicol. 1977, 41, 74–79.
- Kanto, J., L. Kangas & T. Siirtola: Cerebrospinal-fluid concentrations of diazepam and its metabolites in man. Acta pharmacol. et toxicol. 1975, 36, 328–344.
- Kraus, J. W., J. P. Marshall, R. Johnson, G. R. Wilkinson & S. Schenker: Lorazepam elimination in liver disease. Gastroenterology 1977, 73, 1228.
- Rall, D. P. & C. G. Zubrod: Mechanism of drug absortion and excretion. Passage of drugs in and out of the central nervous system. Amer. Rev. Pharmacol. 1962, 2, 109–128.
- Schillings, R. T., R. Shader & H. V. Ruelius: Urinary metabolites of lorazepam in humans and four animal species. Arzneimittelforsch. 1971, 21, 1059–1065.
- Stanski, D. R., D. J. Greenblatt, A. Selwyn, R. I. Shader, K. Franke & J. Koch-Weser: Plasma and cerebspinal fluid concentrations of chlordiazepoxide and its metabolites in surgical patients. Clin. Pharmacol. Therap. 1976, 20, 571–578.
- Verbeeck, R., T. B. Tjandramaga, R. Verberckmoes & P. J. deSchepper: Biotransformation and excretion of lorazepam in patients with chronic renal failure. Brit. J. Clin. Pharmacol. 1976, 3, 1033–1039.
